Current guidelines for the drug treatment of ankylosing spondylitis

Drugs

Volumn 56, Issue 2, 1998, Pages 225-240

  Toussirot, Eric ^a   Wendling, Daniel ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BROMOCRIPTINE; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GOLD SALT; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; METHOTREXATE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PENICILLAMINE; PHENYLBUTAZONE; RIFAMYCIN; SALAZOSULFAPYRIDINE; TETRACYCLINE; UNINDEXED DRUG;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; FLUOROSCOPY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; MALE INFERTILITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PHYSIOTHERAPY; PRACTICE GUIDELINE; QUALITY OF LIFE; REST; RHEUMATIC DISEASE; SACROILIAC JOINT; SKIN TOXICITY; SPINE; STEVENS JOHNSON SYNDROME; VERTIGO;

EID: 0031818027     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856020-00006     Document Type: Article

References (126)

1. Wollheim FA. Ankylosing spondylitis. In Kelley WN, Harris ED. Ruddy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1993: 943-55
2. Toivanen A, Toivanen P. Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Curr Opin Rheumatol 1995; 7: 279-83
3. Ramos-Remus C, Russel AS. Clinical features and management of ankylosing spondylitis. Curr Opin Rheumatol 1993; 5: 408-13
4. Calin A, Elswood J, Rigg S, et al. Ankylosing spondylitis: an analytical review of 1500 patients. The changing pattern of disease. J Rheumatol 1988; 15: 1234-8
5. Ramos-Remus C, Gomez-Vargas A, Guzman-Guzman JS, et al. Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis. J Rheumatol 1995; 22: 2120-5
6. Khan MA, Khan MK, Kushner I. Survival among patients with ankylosing spondylitis: a life-table analysis. J Rheumatol 1981; 8: 86-90
7. Lehtinen K, Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 174-6
8. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumalol 1997; 36: 766-71
9. Amor B, Dougados M, Mijiawu M, Critères de classification des spondylarthropathies. Rev Rheum 1990; 57: 85-9
10. Gran JT, Husby G. Ankylosing spondylitis: current drug treatment. Drugs 1992; 44: 585-603
11. Jackson CG, Clegg DO. The seronegative spondylarthropathies (ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis). In Weisman MH, Weinblatt ME, editors. Treatment of the rheumatic diseases. Philadelphia: Saunders, 1995: 79-92
12. Calin A, Elswood J. A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J Rheumatol 1990; 17: 801-3
13. Laurent R. Are there any antirheumatic drugs that modify the course of ankylosing spondylitis? Baillieres Clin Rheumatol 1990; 4: 387-400
14. Creemer MCW, Van Riel PLCM, Franssen MJAM. Second-line treatment in seronegative spondylarthropathies. Semin Arthritis Rheum 1994; 24: 71-81
15. Clements PJ, Paulus HE. Nonsteroidal anti-inflammatory drugs (NSAIDs). In Kelley WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1993; 700-30
16. Treves R, Desproges-Gotteron R. Les anti-inflaminatoires non stéroïdiens dans la spondylarthrite ankylosante: indication, efficacité, tolérance, incidence sur le pronostic. In: Simon L. Hérisson C, editors. La spondylarthrite ankylosante: actualités nosologiques et thérapeutiques. Paris: Masson, 1988: 103-12
17. Wasner C, Britton MC, Krains EG, et al. Nonsteroidal antiinflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981; 246: 2168-72
18. Boersina JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means ot phenylbutazonc. Scand J Rheumatol 1976; 5: 60-4
19. Calin A, Grahame R. Double-blind cross-over trial of flurbiprofen and phenylbutazone in ankylosing spondylitis. Br Med J 1974: 4: 496-9
20. Calin A, Britton M, Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin. JAMA 1976; 242: 1885-6
21. Wordsworth BP, Ebringer RW, Coggins E, et al. A double-blind trial of fenoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1980; 19: 260-3
22. Treadwell BLJ, Tweed JM. Ketoprofen in ankylosing spondylitis. N Z Med J 1975; 81: 411-3
23. Sydnes OA. Comparison of piroxicam with indomethacin in ankylosing spondylitis. Br J Clin Pract 1981; 35: 40-4
24. Gibson T, Laurent R. Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross over study. Rheumatol Rehabil 1980; 19: 189-92
25. Eberl R. Preliminary results with a new nonsteroidal anti-inflammatory agent, sulindac (MK-231), compared to phenylbulazone in the treatment of ankylosing spondylitis. Scand J Rheumatol 1974; 4 Suppl.: S04-5
26. Van Gerwen F, Van Der Korst JK, Gribnau FWJ. Double blind trial of naproxen and phenylbutazone in ankylosing spondylitis. Ann Rheum Dis 1978; 37; 85-8
27. Lomen PL, Turner LP, Lamborn KR, et al. Flurbiprofen in the treatment of ankylosing spondylitis: a comparison with indomethacin. Am J Med 1986; 80: 127-32
28. Nahir AR, Scharf Y. Comparative study of diclofenac and sulindac in ankylosing spondylitis. Rheumatol Rehabil 1980; 19: 193-8
29. Tannenbaum H, De Coteau WF, Esdaile JM, et al. A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long term follow-up. Current Therapy Res 1984; 36: 426-35
30. Bacon PA. An overview of the efficacy of etodolac in arthritis disorders. Eur J Rheumatol Inflamm 1990; 10: 22-34
31. Shipley M, Berry H, Bloom B. A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis with comments on patient assessment. Rheumatol Rehabil 1980; 19: 122-5
32. Esdaile J, Rothwell R, MacLaughlin K, et al. Double Wind comparison of tolmetin sodium and indomethacin in ankylosing spondylitis. J Rheumatol 1982; 9: 69-74
33. Good A, Mena H. Treatment of ankylosing spondylitis with flurbiprofen and indomethacin. Curr Med Res Opin 1997; 5: 117-21
34. Jessop JD. Double-blind study of ketoprolen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1976; 15 Suppl.: 37-42
35. Burry HC, Siebers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. N Z Med J 1989; 92: 309-11
36. Ansell BM, Major G, Liyanage SP, et al. A comparative study of phenylbutazone and naproxen in ankylosing spondylitis. Ann Rheum Dis 1978; 37: 436-9
37. Gengos D, Pingeos RA, Andrew A. Long term comparison of sulindac and phenylbutazone for treatment of ankylosing spondylitis. Postgrad Med Comm (Special Report) 1979: 51-60
38. Mayrhofer F, Broel H, Eherl W, et al. Tenoxicam versus diclofenac in patients with ankylosing spondylitis. Drug Invest 1990; 2 Suppl. 3: 52-3
39. Byron MA, Steele SA. A double-blind cross-over study comparing tolmetin sodium and naproxen in the treatment of ankylosing spondylitis. Curr Med Res Opin 1982; 7: 670-6
40. Zeidler VH, Kalden J, Josenhans G. Klinische ergebnisse einer duppel Prufung von Naproxen im Vergleich zu Indomethacin hei chronischer Polyarthritis, Spondylitis ankylopoietica und Artrosen. Arzneimittel Forschung 1975; 25: 315-8
41. Khan MA. A double-blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. J Rheumatol 1987; 14: 118-23
42. Battlle-Gualda E, Figueroa M, Ivorra J, et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled trial. J Rheumatol 1996; 23: 1200-6
43. Villa Alcazar LF, De Buergo MA, Lenza HR, et al. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis; a 3 month multicenter comparative trial. J Rheumatol 1996; 23: 1194-9
44. Deklerk F, Van Der Linden SJ. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis with an electronic monitoring device. Br J Rheumatol 1995; 35: 60-5
45. Vane J, Botting R. Mechanisms of action of anti-inflammatory drugs. In Vane J, Botting J, Botting R, editors. Improved nonsteroid anti-inflammatory drugs COX-2 enzyme inhibitors. Lancaster: Kluwer Academic Publishers, 1996: 1-29
46. Pal B. Use of simple analgesics in the treatment of ankylosing spondylitis. Br J Rheumatol 1987; 26: 207-9
47. Koh WH, Pande I, Samuels A, et al. Low dose amitriptyline in ankylosing spondylitis: a short term, double blind, placebo controlled study. J Rheumatol 1997; 24: 2158-61
48. Ward LE. Rheumatoid spondylitis. Arthritis Rheum 1963; 6: 650-7
49. Toussirot E, Wendung D. L'ostéoporose de la spondylarthrite ankylosante. Presse Med 1996; 25: 720-4
50. Ralston SH, Urquhart GDK, Brzeski M, et al. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 1990; 300: 563-5
51. Peppercorn MA. Sulfasalazine: pharmacology, clinical use, toxicity and related new drug development. Ann Intern Med 1984; 3: 377-86
52. Pinals RS. Sulfasalazine in the rheumatic diseases. Semin Arthritis Rheum 1988; 17: 246-59
53. Porter DR, Capell HA. The use of sulphasalazine as a disease modifying antirheumatic drug. Baillieres Clin Rheumatol 1990 Dec; 4 (3): 535-51
54. Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1994; 50: 137-56
55. Wendling D, Rôle de l'intestin dans la physiopathologie des rhumatismes inflammatoires. Rev Rhum 1992; 59: 389-92
56. Mielants H, Veys EM. The gut in spondylarthropathies. J Rheumatol 1990; 17: 7
57. Taggart A, Gardiner P, McEvoy F, et al. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum 1996; 39: 1400-5
58. Chapman CM, Zwillich SH. Olsalazine in ankylosing spondylitis: a pilot study. J Rheumatol 1994; 21: 1699-701
59. McConkey B. Sulphasalazine and ankylosing spondylitis. Br J Rheumatol 1990; 29: 2-3
60. Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984; 101: 878
61. Coelhe Andrade LE, Atra E, Bosi-Ferraz M, et al. Sulfasalazine and ankylosing spondylitis: an open study. Clin Exp Rheumatol 1989; 7: 661-2
62. Dougados M, Boumier P, Amor B. Sulfasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J 1986; 293: 911-4
63. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986; 45: 396-9
64. Nissilä M, Lehtinen K, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of ankylosing spondylitis: a twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988; 33: 1111-6
65. Davis MJ, Dawes PT, Beswick E, et al. Sulfasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 1989; 28: 410-3
66. Corkill MM, Jobanputra P, Gibson T, et al. Controlled trial of sulfasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol 1990; 29: 41-5
67. Fraser SM, Sturrock RD. Evaluation of sulfasalazine in ankylosing spondylitis - an interventional study. Br J Rheumatol 1990; 29: 37-9
68. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis: a radiological, clinical and laboratory assessment. Clin Rheumatol 1991; 10: 43-8
69. Kirwan J, Edwards A, Huitfeldt B, et al. The course of established ankylosing spondylitis and the effects of sulfasalazine over 3 years. Br J Rheumatol 1993; 32: 729-33
70. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996; 39: 2004-12
71. Dougados M, Van Der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618-27
72. Mielants H, Veys EM, Joos R. Sulfasalazine (salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis. Clin Rheumatol 1986; 5: 80-3
73. Bosí-Ferraz M, Tugwell P, Goldsmith C, et al. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17: 1782-6
74. Steven MM, Morrison M, Sturrock RD. Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial. J Rheumatol 1985; 12: 735-7
75. Golding DN. D-Penicillamine in ankylosing spondylitis and polymyositis. Postgrad Med J 1974; 50: 62-5
76. Leca AP, Camus JP. Spondylarthrite ankylosante. Echec du traitement par la D-Pénicillamine [letter]. Nouvelle Presse Med 1975; 4: 112
77. Scharf Y, Nahir M. Penicillamine in ankylosing spondylitis [letter]. Arthritis Rheum 1976; 19: 122
78. Bird HA. Failure of D-penicillamine to affect peripheral joint involvement in ankylosing spondylitis or HLA B27-associated arthropathy [letter]. Ann Rheum Dis 1977; 36: 289
79. Jaffe IA. Penicillamine in seronegative polyarthritis [letter]. Ann Rheum Dis 1977; 36: 289
80. Tytman K, Bernacka K, Sierakowski S. D-Penicillamine in the therapy of ankylosing spondylitis. Clin Rheumatol 1989; 8: 419-20
81. Grasedyck K, Schattenkirchner M, Baudilla K, et al. Zur Behandlung der Spondylitis ankylosans mit Auranofin (ridaura). Z Rheumatol 1990; 49: 98-9
82. Toussirot E, Wendling D, L'utilisation du methotrexate dans les spondylarthropathies: revue de la littérature. Rev Med Interne 1996; 17: 333-9
83. Schnabel A, Gross WL. Low-dose methotrexate in rheumatic disease: efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994; 23: 310-27
84. Handler R. Favorable results using methotrexate in the treatment of patients with ankylosing spondylitis [letter]. Arthritis Rheum 1989; 32: 234
85. Bosi Ferraz M, Carrico DA, Silva H, et al. Low dose methotrexate with leucovorin rescue in ankylosing spondylitis. J Rheumatol 1991; 18: 146-7
86. Sampaio-Barros PD, Costallat LTL, Fernandes SRM, et al. The use of methotrexate in the treatment of ankylosing spondylitis: pilot study [abstract]. Rev Esp Rheumatol 1993; 20 Suppl.: 485
87. Creemers MCW, Franssen MJAM, Van De Putte LBA, et al. Methotrexate in severe ankylosing spondylitis; an open study. J Rheumatol 1995; 22: 1104-7
88. Ostendorf B, Specker C, Schneider M. Ankylosing spondylitis: clinical and serological response to methotrexate therapy compared with rheumatoid arthritis [abstract]. Arthritis Rheum 1995: 38 Suppl.: S203
89. Mintz G, Enriquez RD, Mercado U, et al. Intravenous niethylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis Rheum 1981; 24: 734-6
90. Richter MG, Woo P, Panayi GS, et al. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Rheumatol 1983; 53: 51-9
91. Peters ND, Ejstruo L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992; 21: 134-8
92. Yoshida S, Motai Y, Hattori H, et al. A case of HLA B27 negative ankylosing spondylitis treated with methylprednisolone therapy. J Rheumatol 1993; 20: 1805-6
93. Mercado U. The use of methylprednisolone pulse therapy in a severe case of HLA-B27 negative ankylosing spondylitis [letter]. J Rheumatol 1994; 21: 1582
94. Sadowska-Wroblewska M, Garwolinska H, Maczynska-Rusiniak B. A trial of cyclophosphamide in ankylosing spondylitis with involvement of peripheral joints and high disease activity. Scand J Rheumatol 1986; 15: 259-64
95. Wendling D, Racadot E, Toussirot F, et al. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy [letter]. Br J Rheumatol 1996; 35: 1330
96. Goebel KM, Goebel FD, Schubotz R, et al. Levamisole induced immunostimulation in spondylarthropathies. Lancet 1977; II: 214-7
97. Rosenthal M. A critical review of the effect of levamisole in rheumatic diseases other than rheumatoid arthritis. J Rheumatol 1978; 5: 97-100
98. Veys EM, Mielants H, Verhruggen G, Levamisole-induced adverse reactions in HLA B27 positive rheumatoid arthritis [letter]. Lancet 1978; I: 148
99. Raffayova H. Cyclosporine A (Sandinimun) in the treatment of psoriatic arthritis, ankylosing spondylitis and relapsing polychondritis [abstract]. Scand J Rheumatol 1996, Suppl. 106: 52
100. Storek J, Glaspy JA, Grody WW, et al. Adult-onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis. Am J Hematol 1993; 43: 139-43
101. Bravo G, Zuzueta B, Lavalle C. An acute remission of Reiter's syndrome in male patients treated with hromocriptine. J Rheumatol 1995; 24: 1642-4
102. Eulry F, Bauduceau B, Crozes P, et al. Prolactin response to protiretin in reactive arthritis and ankylosing spondylitis: failure of bromocriptine therapy in four patients with reactive arthritis. Rev Rhum 1994; 61: 766-7
103. Eulry F, Mayaudon H, Lechevallier D. et al. Traitement du rhumatisme psoriasique par la bromocriptine. Presse Med 1995; 24: 1642-4
104. Bravo G. Zazueta B, Felix A, et al. Juvenile ankylosing spondylitis (JAS); direct relation between hyper-prolactinemia and interleukin 6 (IL6) [abstract]. Arthritis Rheum 1994; 37 Suppl.: S428
105. Maksymowych WP, Jhangri GS, Leclercq S, et al. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998; 25: 714-7
106. Mitra D. O'Neill T, Elvins D, et al. The efficacy of etidronate on disease activity, markers of bone turn-over and BMD in patients with early AS and osteoporosis [abstract]. Arthritis Rheum 1994; 38 Suppl.: S349
107. Toussirot E, Despaux J, Wendling D. Do minocycline and other tetracyclines have a place in rheumatology? Rev Rhum 1997; 64: 474-80
108. Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37: 629-36
109. Tilley BC, Arlacon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48 week, double-blind, placebo-controlled trial. Ann Intern Med 1995; 122: 81-9
110. Lauhio A, Leirisalo-Repo M, Lahdevirta J. et al. Double-blind, placebo-controlled study of three month treatment with lymecycline in reactive arthritis with special reference to chlamydia trachomatis. Arthritis Rheum 1991; 34: 6-14
111. Grill V, Smith M, Abern M, et al. Local radiotherapy for pedal manifestation of HLA B27 related arthropathy Br J Rheumatol 1988; 27: 390-2
112. Maugars Y, Mathis C, Vilon P, et al. Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 1992; 35: 564-8
113. Maugars Y, Mathis C, Berthelot JM, et al. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 1996; 35: 767-70
114. Braun J, Bollow M, Seyrekbasan F, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondylarthropathy with sacroiliitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 1996; 23: 659-64
115. Caruso I, Montrone F, Fumagalli M, et al. Rifamycin SV in the treatment of synovitis. Orthopedics 1982; 5: 1336-43
116. Caruso I, Cazzola M, Santadrea S, Clinical improvement in ankylosing spondylitis with rifamycin SV infiltrations of peripheral joints. J Int Med Res 1992; 20: 171-81
117. Dougados M, Berenbaum F, Maetzel A, et al. The use of sulfasalazine for the prevention of attacks of acute anterior uveitis associated with spondylarthropathy. Rev Rhum 1993; 60: 80-2
118. Van Der Linden S, Valkenburg HA. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of New York criteria. Arthritis Rheum 1984; 27: 361-8
119. Laurent MR, Buchanan WW, Bellamy N. Methods of assessment used in ankylosing spondytitis clinical trials: a review. Br J Rheumatol 1991; 30: 326-9
120. Bellamy N, Buchanan WW, Esdaile JM, et al. Ankylosing spondylitis antirheumatic drug trials: I. Effect of standardization procedures on observer dependant outcome measures. J Rheumatol 1991; 18: 1701-8
121. Williams HJ. Clinical trials in rheumatology. Curr Opin Rheumatol 1993; 5: 146-52
122. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis; the Bath Ankylosing Spondylitis Disease Activity. J Rheumatol 1994; 21: 2286-91
123. Kraag G, Stokes B, Groh J, et al. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - a randomized controlled trial. J Rheumatol 1990; 17: 228-33
124. Hess EV. Rheumatoid arthritis: treatment. In Schumacher HR, Klippel JH, Robinson DR. Primer on the rheumatic diseases. 9th ed. Atlanta: Arthritis Foundation, 1989: 93-6
125. Vitanen JV, Suni J, Kautiainen M, et al. Effect of physiotherapy on spinal mobility in ankylosing spondylitis. Scand J Rheumatol 1992; 21: 388-41
126. Koh WH, Garrett SL, Calin A. Cervical spine surgery in ankylosing spondylitis: is the outcome good? Clin Rheumatol 1997; 16: 466-70